It remains unclear what further policies, legislation and/or actions the Administration, Congress, or state governments will advance with respect to other drug pricing proposals or other healthcare regulations affecting pharmaceuticals, including the MFN EO, IRA and OB3 implementation, trade policies, or state laws affecting the 340B Program or Medicaid reimbursement that could ultimately be adopted more broadly. To the extent such actions reduce or modify coverage or reimbursement for our products, increase rebates or other costs, constrain pricing decisions, or otherwise limit product use, they would have an adverse effect on our business and results of operations.
All entries for: Metabolic
April 8, 2026
Inventiva S.A.
Negative Outlook
Mountain View, CA
51-200 employees
If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize future product candidates that we develop, which could have an adverse effect on our operating results and our overall financial condition.
Disease Area: Metabolic, Rare Disease
Drug Type: Small Molecule
February 3, 2026
Amgen Inc
Negative Outlook
Thousand Oaks, CA
10,000+ employees
Other operating expenses for the full year included Otezla® intangible asset impairment charges of $1.2 billion, following the selection of Otezla® for Medicare price setting, as part of the Inflation Reduction Act (IRA).
Disease Area: Cardiovascular, Hematology, Metabolic, Oncology, Rare Disease
Drug Type: Biologic, Small Molecule